Abstract
Combating multiple drug resistance necessitates the delivery of drug molecules at the cellular level. Novel drug delivery formulations have made it possible to improve the therapeutic effects of drugs and have opened up new possibilities for research. Solid lipid nanoparticles (SLNs), a class of colloidal drug carriers made of lipids, have emerged as potentially effective drug delivery systems. The use of SLNs is associated with numerous advantages such as low toxicity, high bioavailability of drugs, versatility in the incorporation of hydrophilic and lipophilic drugs, and the potential for production of large quantities of the carrier systems. The SLNs and nanostructured lipid carriers (NLCs) are the two most frequently used types of nanoparticles. These types of nanoparticles can be adjusted to deliver medications in specific dosages to specific tissues, while minimizing leakage and binding to non-target tissues.
Highlights
Solid lipid nanoparticles (SLNs) are developed as colloidal carrier systems for delivery of water-soluble drugs and for successful correction of dynamic therapy [1]
Adefovir dipivoxil-entrapped solid lipid nanoparticles (SLNs) were developed by incorporating octadecylamine-fluorescein isothiocyanate and reported that SLN-ADV showed enhanced inhibitory effects in in vitro against hepatitis B surface antigen, hepatitis B antigen, and hepatitis B virus DNA levels [47]
In an animal model of herpes simplex virus infection, Kondel et al (2019) established the sustained release of acyclovir from SLNs against the treatment of HSV-1 infection and concluded that acyclovir-SLNs can be offered as a single dosage [48]
Summary
Solid lipid nanoparticles (SLNs) are developed as colloidal carrier systems for delivery of water-soluble drugs and for successful correction of dynamic therapy [1]. The fluid lipid of the O/W emulsion can be replaced by a solid lipid nanoparticle [5] Techniques such as high-pressure homogenization and solvent evaporation are used for the production of SLNs [6,7]. The SLNs have gained a lot of attention because they can ef2foefc tively deliver drugs and genes, and they can be used for targeted therapies [11] They have potential advantages over other nanoparticles due to their superior biocompatibility, increased drug loading capacity, and scalability. In 2002, Müller an3docf o12lleagues proposed the terms solid lipid nanoparticles and nanostructured lipid carriers These arose from a natural idea that combines the advantageous characteristics of NPs fwroimth athnoasteuoraf lniodne-atotxhiactacnodmbbiiondeesgtrhaedaabdlvealniptiadgecooumspcohnaernatcstetroisftoircms onfoNn-Ptsoxwicitahntdhobsioeodfengorand-taobxliecpaanrdenbtieordael gemraudlasbiolenslipthidatccoomulpdobneenadtsmtoinfiostremrendoinn-ttroaxviecnaonudslybi[o1d5e].gradable parenTtehrealneamnouclasirorniesrsthaarteccoluasldsifbieedadbmasiendisotenrethdeiinrtcroamvepnoosuitsiloyn[s1,5r]o. Positive charges on the surface of nanoparticles enhance their binding to cell membranes and normal tissues and promote platelet accumulation and other hemolytic processes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
